{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:28:00Z","timestamp":1793640480979,"version":"4.5.1"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yexmp.2026.105078","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:55:51Z","timestamp":1790121351000},"page":"105078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy"],"prefix":"10.1016","volume":"148","author":[{"given":"Fabrizio","family":"Celesti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2026.105078_bb0005","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1084\/jem.157.3.1053","article-title":"Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets","volume":"157","author":"Accolla","year":"1983","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1084\/jem.164.1.369","article-title":"aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression","volume":"164","author":"Accolla","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0015","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3389\/fimmu.2019.01806","article-title":"CIITA-driven MHC class II expressing tumor cells as antigen presenting cell performers: toward the construction of an optimal anti-tumor vaccine","volume":"10","author":"Accolla","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-023-02628-x","article-title":"Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells","volume":"42","author":"Amaro","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1285895","article-title":"HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker","volume":"14","author":"Amrane","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13046-022-02529-5","article-title":"Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy","volume":"41","author":"Anichini","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.molimm.2007.10.035","article-title":"MicroRNA targets in immune genes and the Dicer\/Argonaute and ARE machinery components","volume":"45","author":"Asirvatham","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0040","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1387835","article-title":"Novel vaccination strategies based on optimal stimulation of CD4+ T helper cells for the treatment of oral squamous cell carcinoma","volume":"15","author":"Azzi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188801","article-title":"Tumoral RCOR2 promotes tumor development through dual epigenetic regulation of tumor plasticity and immunogenicity","volume":"135","author":"Bao","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.yexmp.2026.105078_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0316716","article-title":"MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer","volume":"20","author":"Barbeau","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.yexmp.2026.105078_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148753","article-title":"Degradation, promoter recruitment and transactivation mediated by the extreme N-terminus of MHC class II transactivator CIITA isoform III","volume":"11","author":"Beaulieu","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.yexmp.2026.105078_bb0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fvl-2017-0011","article-title":"Understanding capsid assembly and genome packaging for adeno-associated viruses","volume":"12","author":"Bennett","year":"2017","journal-title":"Future Virol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0070","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/ni1125","article-title":"Intrinsic immunity: a front-line defense against viral attack","volume":"5","author":"Bieniasz","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0075","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/1878-0261.12953","article-title":"Immune modulation underpins the anti-cancer activity of HDAC inhibitors","volume":"15","author":"Blaszczak","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261777","article-title":"CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells","volume":"6","author":"Bou Nasser Eddine","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.yexmp.2026.105078_bb0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1126\/science.abb3753","article-title":"MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses","volume":"370","author":"Bruchez","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.yexmp.2026.105078_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.yexmp.2026.105078_bb0095","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1084\/jem.20180314","article-title":"Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5","volume":"215","author":"Buxad\u00e9","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.yexmp.2026.105078_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1133177","article-title":"Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA","volume":"14","author":"Celesti","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/42030","article-title":"Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells","volume":"388","author":"Cella","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2026.105078_bb0115","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ccell.2022.09.007","article-title":"Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses","volume":"40","author":"Chan","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexmp.2026.105078_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.178.1.27","article-title":"Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles","volume":"178","author":"Chicz","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0125","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11165","article-title":"Transfection types, methods and strategies: a technical review","volume":"9","author":"Chong","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.yexmp.2026.105078_bb0130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.molimm.2007.07.039","article-title":"Spatial distribution of histone methylation during MHC class II expression","volume":"45","author":"Chou","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0135","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/intimm\/dxh326","article-title":"Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells","volume":"17","author":"Chou","year":"2005","journal-title":"Int. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s43856-024-00612-w","article-title":"MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma","volume":"4","author":"Claeys","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0145","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.3389\/fimmu.2019.02923","article-title":"Helicobacter pylori dampens HLA-II expression on macrophages via the up-regulation of miRNAs targeting CIITA","volume":"10","author":"Codolo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00262-012-1365-7","article-title":"Immunomodulatory activity of SGI-110, a 5-aza-2\u2032-deoxycytidine-containing demethylating dinucleotide","volume":"62","author":"Coral","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexmp.2026.105078_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1019978","article-title":"Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models","volume":"4","author":"Covre","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.yexmp.2026.105078_bb0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imm.12136","article-title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma","volume":"140","author":"Cycon","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.yexmp.2026.105078_bb0165","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/intimm\/dxn103","article-title":"Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN- in promyelocytic cells","volume":"20","author":"De Lerma Barbaro","year":"2008","journal-title":"Int. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00476","article-title":"CIITA and its dual roles in MHC gene transcription","volume":"4","author":"Devaiah","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3350\/cmh.2024.0060","article-title":"Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction","volume":"30","author":"Dezhbord","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117111","article-title":"A novel 3-alkenylindol-2-one derivative selectively inhibits the growth of acute myeloid leukemia via modulation of the MYC-PRMT pathway","volume":"240","author":"Dong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007588","article-title":"Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells","volume":"12","author":"Ducellier","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0195","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2767-9764.CRC-23-0399","article-title":"EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas","volume":"4","author":"DuCote","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.yexmp.2026.105078_bb0200","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00262-020-02571-2","article-title":"Characterising the prognostic potential of HLA-DR during colorectal cancer development","volume":"69","author":"Dunne","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexmp.2026.105078_bb0205","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7314\/APJCP.2013.14.2.987","article-title":"Exosomes from CIITA-transfected CT26 cells enhance anti-tumor effects","volume":"14","author":"Fan","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.yexmp.2026.105078_bb0210","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fphar.2018.01443","article-title":"Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy","volume":"9","author":"Fazio","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0215","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/2326-6066.CIR-15-0243","article-title":"Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes","volume":"4","author":"Forero","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2013.00234","article-title":"The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators","volume":"4","author":"Forlani","year":"2013","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-016-0853-5","article-title":"The MHC-II transactivator CIITA inhibits tat function and HIV-1 replication in human myeloid cells","volume":"14","author":"Forlani","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0230","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3390\/cancers12113181","article-title":"Unveiling the hidden treasury: CIITA-driven MHC class II expression in tumor cells to dig up the relevant repertoire of tumor antigens for optimal stimulation of tumor specific CD4+ T helper cells","volume":"12","author":"Forlani","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105078_bb0235","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.RA120.002201","article-title":"CIITA-transduced glioblastoma cells uncover a rich repertoire of clinically relevant tumor-associated HLA-II antigens","volume":"20","author":"Forlani","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.yexmp.2026.105078_bb0240","article-title":"The NLR member CIITA: master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy","volume":"46","author":"Forlani","year":"2023","journal-title":"Biom. J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0245","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/ijc.25183","article-title":"CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy","volume":"127","author":"Frangione","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yexmp.2026.105078_bb0255","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexmp.2026.105078_bb0260","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1186\/s12967-025-06816-5","article-title":"CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas","volume":"23","author":"Gatta","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0265","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41397-019-0138-5","article-title":"Cancer\u2019s epigenetic drugs: where are they in the cancer medicines?","volume":"20","author":"Ghasemi","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0270","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-21-0607","article-title":"Tumor-specific major histocompatibility-II expression predicts benefit to anti\u2013PD-1\/L1 therapy in patients with HER2-negative primary breast cancer","volume":"27","author":"Gonzalez-Ericsson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0275","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.yexmp.2026.105078_bb0280","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1128\/MCB.20.17.6185-6194.2000","article-title":"Class II transactivator: mastering the art of major histocompatibility complex expression","volume":"20","author":"Harton","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101678","article-title":"High expression of tumor HLA-DR predicts better prognosis and response to anti-PD-1 therapy in laryngeal squamous cell carcinoma","volume":"33","author":"Heng","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0290","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0295","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.285616","article-title":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","author":"Hogeling","year":"2024","journal-title":"Haematol"},{"key":"10.1016\/j.yexmp.2026.105078_bb0300","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.4049\/jimmunol.179.8.5317","article-title":"A role for EZH2 in silencing of IFN-\u03b3 inducible MHC2TA transcription in uveal melanoma","volume":"179","author":"Holling","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0305","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1095\/biolreprod.103.017103","article-title":"Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts1","volume":"69","author":"Holtz","year":"2003","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.yexmp.2026.105078_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111680","article-title":"Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA","volume":"41","author":"Hos","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.yexmp.2026.105078_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105057","article-title":"The role of MHC molecules in cancer immunotherapy: insights into tumor immune evasion and therapeutic strategies","volume":"218","author":"Huang","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0320","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1128\/MCB.22.15.5616-5625.2002","article-title":"Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers","volume":"22","author":"Jabrane-Ferrat","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007736","article-title":"Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance","volume":"11","author":"James","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0330","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-026-03673-y","article-title":"The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma","author":"Jin","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexmp.2026.105078_bb0340","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120360","article-title":"Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement","volume":"3","author":"Johnson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.yexmp.2026.105078_bb0345","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.4049\/jimmunol.1900778","article-title":"Cancer cell\u2013intrinsic expression of MHC class II regulates the immune microenvironment and response to anti\u2013PD-1 therapy in lung adenocarcinoma","volume":"204","author":"Johnson","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0350","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.yexmp.2026.105078_bb0355","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.4049\/jimmunol.170.10.4980","article-title":"Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas","volume":"170","author":"Kanaseki","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0360","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1074-7613(00)80159-4","article-title":"Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection","volume":"12","author":"Kanazawa","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.yexmp.2026.105078_bb0365","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218955120","article-title":"FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA","volume":"120","author":"Kasuga","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexmp.2026.105078_bb0370","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev-immunol-051116-052450","article-title":"Unfinished business: evolution of the MHC and the adaptive immune system of jawed vertebrates","volume":"36","author":"Kaufman","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0375","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","article-title":"MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors","volume":"41","author":"Kilian","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexmp.2026.105078_bb0380","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.4049\/jimmunol.180.10.7019","article-title":"Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun","volume":"180","author":"Kim","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0385","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/vaccines12010071","article-title":"DNA vaccines: their formulations, engineering and delivery","volume":"12","author":"Kozak","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.yexmp.2026.105078_bb0390","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.4049\/jimmunol.173.10.6200","article-title":"Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA","volume":"173","author":"Krawczyk","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0395","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.194.4.379","article-title":"Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (Ciita) expression","volume":"194","author":"Landmann","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0400","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1541-7786.MCR-22-0898","article-title":"MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL15 and MHC class II production","volume":"21","author":"Langenbach","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0405","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","article-title":"Cellular vaccine approaches","volume":"16","author":"Le","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0410","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3858\/emm.2011.43.5.029","article-title":"Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects","volume":"43","author":"Lee","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0415","article-title":"The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.yexmp.2026.105078_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119966","article-title":"Astragalus injection antagonizes the efficacy of anti-PD-1 against melanoma through down-regulating MHC-II expression","volume":"349","author":"Lei","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0425","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/eji.200424964","article-title":"Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes","volume":"34","author":"LeibundGut-Landmann","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0430","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002510050202","article-title":"Isolation of a B-cell-specific promoter for the human class II transactivator","volume":"45","author":"Lennon","year":"1997","journal-title":"Immunogenetics"},{"key":"10.1016\/j.yexmp.2026.105078_bb0435","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/ijms22031074","article-title":"The MHC class II transactivator CIITA: not (quite) the odd-one-out anymore among NLR proteins","volume":"22","author":"Le\u00f3n Machado","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.yexmp.2026.105078_bb0440","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.7150\/jca.118933","article-title":"Combined bioinformatics analyses and immunohistochemical validation reveal the prognostic relevance and immune-related role of CIITA in breast cancer","volume":"16","author":"Li","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0445","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/MCB.21.9.3001-3011.2001","article-title":"Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains","volume":"21","author":"Linhoff","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0450","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104813","article-title":"Unlock the code of MHC II-enabled cancer immunotherapy","volume":"214","author":"Liu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0460","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-21-4424","article-title":"Phase I\/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma","volume":"28","author":"L\u00f6ffler","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/epigenomes5040027","article-title":"Epigenetic immune remodeling of mesothelioma cells: a new strategy to improve the efficacy of immunotherapy","volume":"5","author":"Lofiego","year":"2021","journal-title":"Epigenomes"},{"key":"10.1016\/j.yexmp.2026.105078_bb0470","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12967-024-05040-x","article-title":"Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches","volume":"22","author":"Lofiego","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.26478","article-title":"CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells","volume":"131","author":"Londhe","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0480","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/v16030442","article-title":"Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights","volume":"16","author":"Lopez-Gordo","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.yexmp.2026.105078_bb0485","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0490","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36401\/JIPO-25-31","article-title":"Class II major histocompatibility complex transactivator (CIITA): a master MHC-II regulator impacting cancer and beyond","volume":"9","author":"Low","year":"2026","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0495","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0500","article-title":"The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0505","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cell.2018.08.048","article-title":"Evolutionary pressure against MHC class II binding cancer mutations","volume":"175","author":"Marty Pyke","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.yexmp.2026.105078_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175590","article-title":"Use of histone methyltransferase inhibitors in cancer treatment: a systematic review","volume":"944","author":"Marzochi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0515","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gad.14.9.1156","article-title":"CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex","volume":"14","author":"Masternak","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.yexmp.2026.105078_bb0520","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ni883","article-title":"Chromatin remodeling and extragenic transcription at the MHC class II locus control region","volume":"4","author":"Masternak","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0525","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1006\/mthe.2002.0804","article-title":"Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency","volume":"6","author":"Matheux","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexmp.2026.105078_bb0530","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/eji.200323712","article-title":"Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells","volume":"33","author":"Meazza","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0535","doi-asserted-by":"crossref","first-page":"13794","DOI":"10.1073\/pnas.1008684107","article-title":"NLR family member NLRC5 is a transcriptional regulator of MHC class I genes","volume":"107","author":"Meissner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexmp.2026.105078_bb0540","article-title":"High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant","author":"Meng","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexmp.2026.105078_bb0545","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.3390\/cancers13153907","article-title":"Distinct molecular mechanisms of altered HLA class II expression in malignant melanoma","volume":"13","author":"Meyer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105078_bb0550","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2026.105078_bb0555","article-title":"Single-cell analysis highlights the significance of malignant cell IFN\/MHC-II for immunotherapy response in head and neck squamous cell carcinoma","volume":"7","author":"Mints","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0560","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","article-title":"Suppression of antigen presentation by IL-10","volume":"34","author":"Mittal","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0565","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.4049\/jimmunol.164.8.4143","article-title":"Methylation of class II trans -activator promoter IV: a novel mechanism of MHC class II gene control","volume":"164","author":"Morris","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0570","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1128\/MCB.22.13.4781-4791.2002","article-title":"Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation","volume":"22","author":"Morris","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0575","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1158\/1078-0432.CCR-06-0165","article-title":"CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory","volume":"12","author":"Mortara","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0580","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/intimm\/dxp034","article-title":"Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions","volume":"21","author":"Mortara","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0585","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/emboj\/16.10.2851","article-title":"Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA","volume":"16","author":"Muhlethaler-Mottet","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0590","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(00)80468-9","article-title":"Activation of the MHC class II transactivator CIITA by interferon-\u03b3 requires cooperative interaction between Stat1 and USF-1","volume":"8","author":"Muhlethaler-Mottet","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.yexmp.2026.105078_bb0595","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD4+ T cells in PD-1 blockade against MHC-II\u2013expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.yexmp.2026.105078_bb0600","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1779991","article-title":"Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy","volume":"9","author":"Naseri","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.yexmp.2026.105078_bb0605","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0610","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.4049\/jimmunol.1103136","article-title":"NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner","volume":"188","author":"Neerincx","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0615","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.4049\/jimmunol.1401065","article-title":"The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression","volume":"193","author":"Neerincx","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0620","doi-asserted-by":"crossref","first-page":"14611","DOI":"10.1073\/pnas.0503070102","article-title":"Apical role for BRG1 in cytokine-induced promoter assembly","volume":"102","author":"Ni","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexmp.2026.105078_bb0625","doi-asserted-by":"crossref","first-page":"19089","DOI":"10.1074\/jbc.M101295200","article-title":"Dendritic cell-specific MHC class II Transactivator contains a caspase recruitment domain that confers potent transactivation activity","volume":"276","author":"Nickerson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexmp.2026.105078_bb0630","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/2159-8290.CD-21-1357","article-title":"The spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution","volume":"12","author":"Nirmal","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexmp.2026.105078_bb0635","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1038\/s41467-023-40994-4","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial","volume":"14","author":"Noviello","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexmp.2026.105078_bb0640","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.yexmp.2026.105078_bb0645","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1275::AID-IMMU1275>3.0.CO;2-T","article-title":"Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-\u03b2, IL-4, IL-13 and IL-10","volume":"29","author":"O\u2019Keefe","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0650","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/gt.2017.25","article-title":"Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo","volume":"24","author":"Palma","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.yexmp.2026.105078_bb0655","article-title":"Computational network biology analysis revealed COVID-19 severity markers: molecular interplay between HLA-II with CIITA","volume":"20","author":"Park","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.yexmp.2026.105078_bb0660","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/94.11.805","article-title":"Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?","volume":"94","author":"Parmiani","year":"2002","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.yexmp.2026.105078_bb0665","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","article-title":"Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response","volume":"129","author":"P\u00e9rez-Ba\u00f1os","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0670","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/2767-9764.CRC-23-0091","article-title":"MHC class II is induced by IFN\u03b3 and follows three distinct patterns of expression in colorectal cancer organoids","volume":"3","author":"Pickles","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.yexmp.2026.105078_bb0675","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/82788","article-title":"BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells","volume":"1","author":"Piskurich","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0680","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo8043","article-title":"Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma","volume":"8","author":"Piunti","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.yexmp.2026.105078_bb0685","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","article-title":"The role of CD4 T cells in rejection of solid tumors","volume":"74","author":"Poncette","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0690","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","article-title":"Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","volume":"207","author":"Quezada","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0695","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1548243","article-title":"CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches","volume":"8","author":"Ramia","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.yexmp.2026.105078_bb0700","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s44318-024-00306-y","article-title":"ZBTB48 is a priming factor regulating B-cell-specific CIITA expression","volume":"43","author":"Rane","year":"2024","journal-title":"EMBO J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0705","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/2326-6066.CIR-22-0157","article-title":"BCG-induced tumor immunity requires tumor-intrinsic CIITA independent of MHC-II","volume":"10","author":"Redelman-Sidi","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0710","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/0008-5472.CAN-24-2772","article-title":"Dasatinib remodels the tumor microenvironment and sensitizes small cell lung cancer to immunotherapy","volume":"85","author":"Redin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0715","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0720","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","article-title":"Present yourself! By MHC class I and MHC class II molecules","volume":"37","author":"Rock","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0725","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0730","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.yexmp.2026.105078_bb0735","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/353622a0","article-title":"Sequence analysis of peptides bound to MHC class II molecules","volume":"353","author":"Rudensky","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2026.105078_bb0740","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/1878-0261.13750","article-title":"Adenoviral delivery of the CIITA transgene induces T-cell-mediated killing in glioblastoma organoids","volume":"19","author":"Salvato","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0745","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.3390\/ijms24087206","article-title":"NLRC5-CIITA fusion protein as an effective inducer of MHC-I expression and antitumor immunity","volume":"24","author":"Santharam","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.yexmp.2026.105078_bb0750","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1038\/sj.onc.1208144","article-title":"Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-\u03b3-induced HLA-DR expression in colorectal and gastric cancer cells","volume":"23","author":"Satoh","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.yexmp.2026.105078_bb0755","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/eji.200323490","article-title":"N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA","volume":"33","author":"Schnappauf","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0760","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1593\/neo.131568","article-title":"HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker","volume":"16","author":"Sconocchia","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.yexmp.2026.105078_bb0765","article-title":"New concepts for glioblastoma vaccine immunotherapy","volume":"100974","author":"Shallak","year":"2026","journal-title":"Biom. J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101727","article-title":"The impact of immunopeptidomics: from basic research to clinical implementation","volume":"66","author":"Shapiro","year":"2023","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0775","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.ijbiomac.2021.05.192","article-title":"A review of the tortuous path of nonviral gene delivery and recent progress","volume":"183","author":"Sharma","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0780","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biocel.2005.07.012","article-title":"Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription","volume":"38","author":"Shi","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0785","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0790","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.3390\/cancers12113374","article-title":"Tumor MHC expression guides first-line immunotherapy selection in melanoma","volume":"12","author":"Shklovskaya","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105078_bb0795","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/MCB.21.15.4919-4928.2001","article-title":"Self-association of CIITA and its transactivation potential","volume":"21","author":"Sisk","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0800","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/glia.1125","article-title":"Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-\u03b3-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+ T-cell activation","volume":"36","author":"Soos","year":"2001","journal-title":"Glia"},{"key":"10.1016\/j.yexmp.2026.105078_bb0805","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","article-title":"Regulation of MHC class II expression by interferon-\u03b3 mediated by the transactivator gene CIITA","volume":"265","author":"Steimle","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.yexmp.2026.105078_bb0810","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2026.105078_bb0815","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ajt.2025.01.037","article-title":"High mobility group box-1 protein\u2013mediated class II major histocompatibility complex transactivator superenhancers are critical for dendritic cell\u2013trained immunity in acute-to-chronic progression of allograft rejection","volume":"25","author":"Sun","year":"2025","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.yexmp.2026.105078_bb0820","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/glia.10343","article-title":"Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA)","volume":"45","author":"Takamura","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.yexmp.2026.105078_bb0825","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3324\/haematol.2018.205567","article-title":"Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia\/lymphoma","volume":"104","author":"Takeuchi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2026.105078_bb0830","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/cancers16010193","article-title":"Limited effects of class II transactivator-based immunotherapy in murine and human glioblastoma","volume":"16","author":"Tan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105078_bb0835","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3390\/cells13221883","article-title":"Non-immune-mediated, p27-associated, growth inhibition of glioblastoma by class-II-transactivator (CIITA)","volume":"13","author":"Tan","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.yexmp.2026.105078_bb0840","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3727\/096504014X13983417587320","article-title":"Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice","volume":"21","author":"Tao","year":"2014","journal-title":"Oncol. Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0845","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3324\/haematol.2022.280014","article-title":"PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion","volume":"108","author":"Taylor","year":"2022","journal-title":"Haematol"},{"key":"10.1016\/j.yexmp.2026.105078_bb0850","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/0008-5472.CAN-05-2289","article-title":"Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0855","doi-asserted-by":"crossref","DOI":"10.1172\/JCI191781","article-title":"Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers","volume":"135","author":"Tiedje","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.yexmp.2026.105078_bb0860","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-22-3714","article-title":"Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors","volume":"29","author":"Toker","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0865","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1093\/emboj\/cdf557","article-title":"Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters","volume":"21","author":"Tosi","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.yexmp.2026.105078_bb0870","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-024-01698-8","article-title":"Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception","volume":"16","author":"Tovar Perez","year":"2024","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.yexmp.2026.105078_bb0875","doi-asserted-by":"crossref","first-page":"44159","DOI":"10.18632\/oncotarget.17395","article-title":"Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth","volume":"8","author":"Turner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexmp.2026.105078_bb0880","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0165-0378(01)00115-2","article-title":"Transcriptional control of MHC genes in fetal trophoblast cells","volume":"52","author":"Van Den Elsen","year":"2001","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0885","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ijc.1623","article-title":"Lack of ifn-\u03b3-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines","volume":"97","author":"Van Der Stoep","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2026.105078_bb0890","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.bcp.2011.05.026","article-title":"Epigenetic regulation of CIITA expression in human T-cells","volume":"82","author":"Van Eggermond","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0895","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0900","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.2147\/OTT.S214231","article-title":"Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment","volume":"12","author":"Wang","year":"2019","journal-title":"OTT"},{"key":"10.1016\/j.yexmp.2026.105078_bb0905","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0910","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-024-01618-6","article-title":"NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0915","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1038\/s41598-025-88972-8","article-title":"Using major histocompatibility complex (MHC) II expression to predict antitumor response to CD4 + lymphocyte depletion","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexmp.2026.105078_bb0920","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12951-025-03433-8","article-title":"Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems","volume":"23","author":"Wang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0925","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40364-025-00797-9","article-title":"Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0930","article-title":"Regulatory mechanisms of ALKBH5\/CIITA axis in the synergistic modulation of hepatocellular carcinoma radiotherapy and immunotherapy","author":"Wang","year":"2026","journal-title":"Genes Immun."},{"key":"10.1016\/j.yexmp.2026.105078_bb0935","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/eji.202048746","article-title":"Cross talk between human regulatory T cells and antigen-presenting cells: lessons for clinical applications","volume":"51","author":"Wardell","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0940","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.it.2006.07.007","article-title":"Epigenetic regulation of MHC-II and CIITA genes","volume":"27","author":"Wright","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0945","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.20091921","article-title":"Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma","volume":"207","author":"Xie","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101463","article-title":"Lipid nanoparticles: composition, formulation, and application","volume":"33","author":"Xu","year":"2025","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.yexmp.2026.105078_bb0955","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.263151","article-title":"Dynamic tumor-specific MHC-II immuno-PET predicts checkpoint inhibitor immunotherapy efficacy in melanoma","author":"Yang","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb0960","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12951-024-02298-7","article-title":"Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application","volume":"22","author":"Yang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.757137","article-title":"MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer","volume":"10","author":"Yi","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.111031","article-title":"LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1\/SOCS1 and STAT1\/CIITA pathways to promote the progression of non-small cell lung cancer","volume":"115","author":"Yin","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.yexmp.2026.105078_bb0975","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.yexmp.2026.105078_bb0980","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1158\/2326-6066.CIR-22-0227","article-title":"Hippo signaling pathway regulates cancer cell\u2013intrinsic MHC-II expression","volume":"10","author":"Zeng","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb0985","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072651","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexmp.2026.105078_bb0990","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179703","article-title":"An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models","volume":"135","author":"Zhang","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.yexmp.2026.105078_bb0995","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1158\/0008-5472.CAN-24-4383","article-title":"Tumor-specific MHC-II activates CD4+ and CD8+ T cells in head and neck squamous cell carcinoma to boost immunotherapy efficacy","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2026.105078_bb1000","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11010-025-05411-y","article-title":"CIITA was involved in regulating ACSL4-dependent ferroptosis in gastric cancer cells","volume":"481","author":"Zhang","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.yexmp.2026.105078_bb1005","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.3390\/cancers16203459","article-title":"CCL21 induces plasmacytoid dendritic cell migration and activation in a mouse model of glioblastoma","volume":"16","author":"Zhao","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105078_bb1010","first-page":"1","article-title":"Biological mechanism and immune response of MHC-II expression in tumor cells","author":"Zhou","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.yexmp.2026.105078_bb1015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.yexmp.2026.105078_bb1020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coi.2004.11.008","article-title":"Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes","volume":"17","author":"Zika","year":"2005","journal-title":"Curr. Opin. Immunol."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480026000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480026000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:52:49Z","timestamp":1793638369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480026000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":204,"alternative-id":["S0014480026000572"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105078","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105078"}}